Bausch + Lomb sets October 28 results date. Bausch + Lomb stock stands at EUR 15.25.

Published on 10/05/2026 at 15:37 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Bausch + Lomb stock costs EUR 15.25 on October 5, 2026 after EUR 15.15, plus 0.66 percent. Results are due October 28, 2026.

BLCO, CA0717051076, Illustration mit AI erstellt.

Bausch + Lomb (ISIN CA0717051076) was trading at EUR 15.25 at Lang & Schwarz on October 5, 2026 at 3:30 p.m. CEST, up 0.66 percent versus the prior close of EUR 15.15. Las Vegas Sun reported on October 5, 2026 that the company will release its third-quarter financial results on October 28, 2026.

October 28 sets the next test

The release will be followed by a conference call at 8:00 a.m. ET, giving investors a defined checkpoint for revenue growth, profitability and the company outlook. The event date is the clearest near-term reference point for BLCO stock after a second quarter that delivered higher sales but still showed pressure at the earnings line.

Bausch + Lomb operates across vision care, ophthalmic pharmaceuticals and surgical products. Its investor-relations page identifies the company as listed on both the NYSE and TSX, while its business covers contact lenses, prescription and over-the-counter eye products, and surgical devices.

Revenue growth meets an earnings miss

According to MarketBeat on September 22, 2026, second-quarter 2026 revenue rose 9.10 percent year over year to USD 1.39 billion, while earnings per share came in at USD 0.15 versus a USD 0.16 consensus estimate. Revenue therefore exceeded the USD 1.37 billion estimate, but earnings per share missed by USD 0.01.

The mixed result matters because the sales comparison is positive while the earnings comparison remains negative. That combination puts the October report in a position to show whether growth is translating into stronger profitability rather than only expanding the top line.

Analysts see a wider valuation gap

Markets Insider reported on September 9, 2026 that Leerink initiated coverage with an Outperform rating and a USD 24.00 price target. The report highlighted dry-eye products, a potential combination product moving toward phase 3 trials and surgical intraocular lenses as factors behind the target.

MarketBeat listed a consensus Hold rating from 15 brokerages on September 22, 2026, with six Buy ratings, eight Holds and one Sell rating. The average target was USD 19.15, leaving the analyst view above the NYSE quotation even though the consensus label remained cautious.

BLCO remains below its yearly high

On the NYSE, BLCO was last at USD 17.13 on October 5, 2026 at 9:34 a.m. ET, with a 52-week range of USD 13.77 to USD 18.92. The USD 17.13 quotation stood 9.46 percent below the 52-week high, while market capitalization was USD 6.1 billion. The Lang & Schwarz reference price was EUR 15.25, plus 0.66 percent versus the EUR 15.15 prior close.